ASTRO: Standard-Dose CRT Beats Higher Dose in Stage III NSCLC

Share this content:
ASTRO: Standard-Dose CRT Beats Higher Dose in Stage III NSCLC
ASTRO: Standard-Dose CRT Beats Higher Dose in Stage III NSCLC

WEDNESDAY, Sept. 27, 2017 (HealthDay News) -- For patients with stage III non-small-cell lung cancer, standard-dose (SD) chemoradiation therapy is better than high-dose (HD) treatment, with higher five-year overall survival rates, according to a study presented at the annual meeting of the American Society for Radiation Oncology (ASTRO), held from Sept. 24 to 27 in San Diego.

Jeffrey D. Bradley, M.D., from the Washington University School of Medicine in St. Louis, and colleagues conducted a phase III randomized trial to compare SD (60 Gy) with high-dose (HD; 74 Gy) chemoradiation therapy and to assess the efficacy of cetuximab for 496 patients with stage III non-small-cell lung cancer. Patients were followed for a median of 5.1 years for the primary end point of overall survival.

The researchers found that for the SD and HD arms, the median overall survival was 28.7 versus 20.3 months, respectively. The five-year overall survival rates were 32.1 versus 23 percent (P = 0.004), and progression-free survival rates were 18.3 versus 13 percent (P = 0.055), favoring the SD arm. In multivariable analysis, factors affecting overall survival included radiation dose favoring SD, tumor location, institution accrual volume, esophagitis/dysphagia, planning target volume, and V5 heart dose/volume. Cetuximab use conferred no benefit.

"This report also confirms that using a higher radiation dose is not beneficial and can lead to detrimental outcomes including lower survival rates and increased side effects," Bradley said in a statement.

Several authors disclosed financial ties to medical technology and pharmaceutical companies. Eli Lilly provided funding for the study.

News Release/Abstract
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Jury Awards 4.62B in Johnson  Johnson Talcum Powder Lawsuit

Jury Awards $4.62B in Johnson & Johnson Talcum ...

The award includes $550 million in compensatory damages and $4.14 billion in punitive damages

100 Now Sickened by Salmonella-Tainted Honey Smacks Cereal

100 Now Sickened by Salmonella-Tainted Honey Smacks Cereal

Thirty people have been hospitalized, but no deaths have been reported

Data Support FDA Restrictions on Child Cough and Cold Medicines

Data Support FDA Restrictions on Child Cough and ...

Surveillance data showed more adverse events for children exposed to hydrocodone than codeine

is free, fast, and customized just for you!




Already a member?

Sign In Now »